Celgene Corporation  

(Public, NASDAQ:CELG)   Watch this stock  
Find more results for CELG
103.41
-4.62 (-4.28%)
Apr 29 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 102.39 - 108.34
52 week 92.98 - 140.72
Open 106.06
Vol / Avg. 6.94M/5.10M
Mkt cap 78.03B
P/E 50.03
Div/yield     -
EPS 2.07
Shares 781.66M
Beta 1.19
Inst. own 82%
Jun 16, 2016
Celgene Corp Annual Shareholders Meeting (Estimated) - 1:00PM EDT - Add to calendar
May 25, 2016
Celgene Corp at UBS Global Healthcare Conference - 10:30AM EDT - Add to calendar
May 11, 2016
Celgene Corp at Bank of America Merrill Lynch Health Care Conference - 12:20PM EDT - Add to calendar
Apr 28, 2016
Q1 2016 Celgene Corp Earnings Release
Apr 28, 2016
Q1 2016 Celgene Corp Earnings Call
Mar 16, 2016
Celgene Corp at Barclays Global Healthcare Conference
Mar 9, 2016
Celgene Corp at Raymond James Institutional Investors Conference
Mar 8, 2016
Celgene Corp at Cowen Health Care Conference
Feb 24, 2016
Celgene Corp at RBC Capital Markets Healthcare Conference
Feb 11, 2016
Celgene Corp at Leerink Partners Global Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '15) 2015
Net profit margin 21.89% 17.31%
Operating margin 34.27% 23.83%
EBITD margin - 32.01%
Return on average assets 8.27% 7.22%
Return on average equity 39.85% 25.75%
Employees 6,971 -
CDP Score - 97 C

Address

86 Morris Ave
SUMMIT, NJ 07901-3915
United States - Map
+1-908-6739000 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Transcripts - SeekingAlpha

Description

Celgene Corporation (Celgene) is a biopharmaceutical company. The Company together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. The Company's primary commercial stage products include REVLIMID (lenalidomide), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), POMALYST/IMNOVID (pomalidomide), VIDAZA, azacitidine for injection (generic version of VIDAZA), THALOMID (thalidomide), OTEZLA (apremilast) and ISTODAX (romidepsin). The Company's clinical trial activity includes trials across the disease areas of hematology, oncology, and inflammation and immunology.

Officers and directors

Robert J. Hugin Executive Chairman of the Board
Age: 61
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Jacqualyn A. Fouse Ph.D. President, Chief Operating Officer, Director
Age: 54
Bio & Compensation  - Reuters
Mark J. Alles Chief Executive Officer, Director
Age: 56
Bio & Compensation  - Reuters
Peter N. Kellogg Chief Financial Officer, Executive Vice President
Age: 59
Bio & Compensation  - Reuters
Thomas O. Daniel M.D. Chairman - Celgene Research
Age: 61
Bio & Compensation  - Reuters
Scott A. Smith Global President - Inflammation & Immunology
Age: 53
Bio & Compensation  - Reuters
Rupert Vessey President - Research and Early Development
Bio & Compensation  - Reuters
Robert M. Hershberg M.D., Ph.D. Chief Scientific Officer
Age: 50
Bio & Compensation  - Reuters
Michael D. Casey Lead Independent Director
Age: 69
Bio & Compensation  - Reuters
Michael W. Bonney Director
Age: 57
Bio & Compensation  - Reuters